DOI 10.5414/CP201894

Int. Journal of Clinical Pharmacology and Therapeutics, Volume 52 - January (1 - 7)

Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions

Beatrice Augendre-Ferrante1, Hernan Picard1, David Evans1, Hafida Arkoub1, Sireesha Pamulapati2, Serge Perrot3, Paul Valensi4, Frederic Rouillon5
1 Lilly France, Medical Department, Biomedicines, Neuilly sur Seine Cedex, France, 2 Lilly UK, Windlesham, Surrey, United Kingdom, 3 Pain Center, Department of Internal Medicine, Hotel Dieu Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris, 4 Department of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, Bondy, 5 Clinique des Maladie Mentales et de l‘Encephale, Sainte Anne Hospital, Paris, France

Abstract

Duloxetine is a serotonin and norepinephrine reuptake inhibitor approved in the European Union for the treatment of major depressive disorder, generalized anxiety disorder, and diabetic peripheral neuropathic pain in adults. This study aimed to assess the real-world conditions of duloxetine use in France. Between April 2009 and January 2010, 290 dispensing pharmacies, randomly selected from a nationally representative list, included 1,104 patients who presented a duloxetine prescription and consented to the study. Demographic, clinical, and prescription data were extracted from pharmacy records and requested from prescribing physicians. Of the 294 patients with full data available, the mean age (standard deviation) was 54.5 (13.5) years; 74.1% were female; and 86.7% presented with a renewal prescription. 73.5% of patients had major depressive disorder; 3.4% generalized anxiety disorder; and 3.4% diabetic peripheral neuropathic pain. Overall, 78.2% (95% CI: 73.1; 82.8) of patients received duloxetine for an EU-approved indication; 95.2% (95% CI: 92.1; 97.4) of patients had no contra-indication to duloxetine; and 99.0% (95% CI: 97.0; 99.8) received an approved dose. Combining these three criteria, the overall approved use of duloxetine was 73.7% (95% CI: 68.3; 78.7). The strengths and limitations of the study design are discussed.

Author Details

Authors

  • Beatrice Augendre-Ferrante1
  • Hernan Picard1
  • David Evans1
  • Hafida Arkoub1
  • Sireesha Pamulapati2
  • Serge Perrot3
  • Paul Valensi4
  • Frederic Rouillon5

Departments

  • 1 Lilly France, Medical Department, Biomedicines, Neuilly sur Seine Cedex, France,
  • 2 Lilly UK, Windlesham, Surrey, United Kingdom,
  • 3 Pain Center, Department of Internal Medicine, Hotel Dieu Hospital, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris,
  • 4 Department of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, Bondy,
  • 5 Clinique des Maladie Mentales et de l‘Encephale, Sainte Anne Hospital, Paris, France

Full Text

Add to Cart

Rights / Permissions

This section will be available soon


Shopping Overview
Type Qtty Price
Your basket is empty
View Cart